📰 Alacyclovir News
Page 7 - Alacyclovir News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alacyclovir. Real-time updates on events, politics, business and more.
November 22, 2022
"Monoclonals had their day, like the Model T or the biplane," Carl Dieffenbach, director of the Division of AIDS at the National Institutes of Health and lead of the NIHs Antiviral Program for Pandemics.
November 21, 2022
Recommendations to manage an unprecedented wave of infections include extra doses of antiviral therapy for children at high risk.
November 17, 2022
The potential first-in-class antisense RNA-based therapy led to sustained clearance of HBsAg and HBV DNA for 24 weeks after treatment ended in the phase 2b study.
November 10, 2022
A panel of outside advisers to the US health regulator on Wednesday voted against authorizing Verus drug for treating high-risk patients hospitalized with COVID-19, citing multiple concerns over efficacy and safety data being based on a small trial.
November 7, 2022
People who took Paxlovid had a 26% reduced risk of developing symptoms of long COVID such as fatigue and shortness of breath.
November 5, 2022
The indication for the nucleoside analog reverse transcriptase inhibitor in children aged 12 years and older is based on safety and efficacy data from a placebo-controlled clinical trial.
November 3, 2022
The risk of shedding was higher in those with primary HSV infections, said researchers.
October 28, 2022
Gilead Sciences on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.
October 28, 2022
The National Institutes of Healths $1 billion RECOVER Initiative has picked Pfizer Incs antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday.
October 14, 2022
A new review paper tackles potential drug-drug interactions with the antiviral drug and todays most commonly prescribed cardiovascular drugs.